【New Stock Listing】BIOKIN (2615) subscription entry fee is 39,293 yuan, and 5 funds including the US-listed pharmaceutical company BMS are invested in the stock
I'm PortAI, I can summarize articles.
BIOKIN (2615) is offering shares for subscription today until November 12, planning to globally issue 8.6343 million H shares, with an entry fee of HKD 39,292.31, and is expected to be listed on November 17. This offering has introduced cornerstone investors, including Bristol-Myers Squibb (BMS), who have collectively subscribed for approximately USD 32 million. The net fundraising amount is about HKD 3.018 billion, primarily for research and development and global supply chain construction. BIOKIN focuses on the research and development of biopharmaceuticals, reporting a loss of RMB 1.12 billion in the first half of 2023
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: etnet The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments